SU

SUSMED, Inc.

Develops digital therapeutics (DTx) and AI systems to streamline clinical development.

4263 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目7番2号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

SUSMED, Inc. is a research and development-focused company that promotes digital medicine under the concept of "sustainable medicine." The company's business is centered on two main pillars: the development of therapeutic smartphone applications (Digital Therapeutics/DTx) for various diseases, such as its government-approved app for insomnia, and the provision of digital systems to support and streamline clinical development for pharmaceutical companies. SUSMED leverages technologies, including AI and blockchain, to enhance the efficiency of clinical trials and create new medical solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-26 08:32
Regulatory News Service
確認書
Japanese 8.6 KB
2025-09-26 08:31
Annual Report
有価証券報告書-第10期(2024/07/01-2025/06/30)
Japanese 1.9 MB
2025-02-14 07:30
Interim Report
確認書
Japanese 8.6 KB
2025-02-14 07:30
Interim Report
半期報告書-第10期(2024/07/01-2025/06/30)
Japanese 230.1 KB
2024-09-27 08:03
Post-Annual General Meeting Information
臨時報告書
Japanese 29.8 KB
2024-09-27 08:02
Governance Information
内部統制報告書-第9期(2023/07/01-2024/06/30)
Japanese 22.5 KB
2024-09-27 08:01
Registration Form
確認書
Japanese 8.6 KB
2024-09-27 08:01
Annual Report
有価証券報告書-第9期(2023/07/01-2024/06/30)
Japanese 1.9 MB
2024-05-10 08:01
Regulatory News Service
確認書
Japanese 8.6 KB
2024-05-10 08:00
Quarterly Report
四半期報告書-第9期第3四半期(2024/01/01-2024/03/31)
Japanese 181.5 KB
2024-02-14 07:01
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-14 07:00
Quarterly Report
四半期報告書-第9期第2四半期(2023/10/01-2023/12/31)
Japanese 206.2 KB
2023-11-10 09:05
Regulatory News Service
確認書
Japanese 8.6 KB
2023-11-10 09:03
Quarterly Report
四半期報告書-第9期第1四半期(2023/07/01-2023/09/30)
Japanese 183.3 KB
2023-09-29 08:04
Post-Annual General Meeting Information
臨時報告書
Japanese 26.0 KB

Automate Your Workflow. Get a real-time feed of all SUSMED, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SUSMED, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan 7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.